Patent controversy embroils South Korean biotech claiming key CRISPR IP

Patent controversy embroils South Korean biotech claiming key CRISPR IP

Questions emerge about whether ToolGen properly acquired foundational gene editing patents, and how much government support founder Kim Jin-soo received for his breakthrough invention.

Unlock unlimited access to all IAM content